Indication
Endometrial Clear Cell Adenocarcinoma
11 clinical trials
15 products
5 drugs
Clinical trial
First-in-Human, Phase 1 Study of AMT-151, an Anti-Folate Receptor Alpha Antibody-Drug Conjugate, in Patients With Selected Advanced Solid TumoursStatus: Recruiting, Estimated PCD: 2024-01-01
Product
AMT-151Clinical trial
A Phase 1B Study of Combination ATR (M1774) and BET Inhibition (ZEN00-3694) to Exploit ARID1A Loss in Recurrent Ovarian and Endometrial CancerStatus: Recruiting, Estimated PCD: 2026-04-30
Product
ZEN-3694Product
TuvusertibClinical trial
A Randomized Phase II Trial of Nivolumab and Ipilimumab Compared to Nivolumab Monotherapy in Patients With Deficient Mismatch Repair System Recurrent Endometrial CarcinomaStatus: Recruiting, Estimated PCD: 2026-04-30
Product
IpilimumabProduct
NivolumabClinical trial
A Phase 1 Study of MLN0128 and Bevacizumab in Patients With Recurrent Glioblastoma and Other Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2020-12-31
Product
BevacizumabProduct
SapanisertibClinical trial
Targeted Complex Therapy for Advanced Melanoma, Gynecologic Cancers, and Other Malignancies: Nab-Paclitaxel (Abraxane)/Bevacizumab Complex (AB-Complex)Status: Active (not recruiting), Estimated PCD: 2024-06-30
Drug
AtezolizumabDrug
AbraxaneClinical trial
Phase I Trial of Intravenous Administration of Vesicular Stomatitis Virus Genetically Engineered to Express Thyroidal Sodium Iodide Symporter (NIS) and Human Interferon Beta (hIFNb), in Patients With Metastatic or Recurrent Endometrial CancerStatus: Active (not recruiting), Estimated PCD: 2024-06-01
Product
Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide SymporterProduct
RuxolitinibClinical trial
A Phase 2 Study of XL184 (Cabozantinib) in Recurrent or Metastatic Endometrial CancerStatus: Active (not recruiting), Estimated PCD: 2019-09-12
Product
CabozantinibClinical trial
A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial CancerStatus: Active (not recruiting), Estimated PCD: 2022-12-16
Drug
AN0025Drug
TiragolumabDrug
mFOLFOX6Clinical trial
A Three Arm Randomized Phase II Study of Paclitaxel/Carboplatin/Bevacizumab (NSC #704865), Paclitaxel/Carboplatin/Temsirolimus (NSC #683864) and Ixabepilone (NSC #710428)/Carboplatin/Bevacizumab as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial CancerStatus: Active (not recruiting), Estimated PCD: 2015-01-31
Clinical trial
A Phase II Trial of DCTD-Sponsored Dasatinib in Recurrent/Persistent Ovary, Fallopian Tube, Primary Peritoneal, and Endometrial Clear Cell Carcinoma Characterized for the Retention or Loss of BAF250a ExpressionStatus: Terminated, Estimated PCD: 2017-02-06
Product
DasatinibProduct
IxabepiloneProduct
TemsirolimusClinical trial
Prospective Evaluation of Lymph Node Metastasis at the Time of Surgical Staging for High Risk Endometrial CancerStatus: Active (not recruiting), Estimated PCD: 2025-04-30
Product
Indocyanine Green